Cullinan Therapeutics Price Target Raised to $35.00/Share From $30.00 by HC Wainwright & Co.
Ratings actions from Benzinga: GMT) Cullinan Therapeutics Is Maintained at Buy by HC Wainwright & Co.Ratings actions from Benzinga
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.